IN THE HIGH COURT OF NEW ZEALAND AUCKLAND REGISTRY
I TE KŌTI MATUA O AOTEAROA TĀMAKI MAKAURAU ROHE
CIV-2023-404-003051
[2025] NZHC 913
BETWEEN MEDTECH LIMITED
Plaintiff
AND
VALENTIA TECHNOLOGIES (NZ) LIMITED
Defendant
Hearing: 6 March 2025 Appearances:
A Ross KC and O Sutton for Plaintiff
K T Glover and D T D Horton for Defendant
Judgment:
15 April 2025
JUDGMENT OF ANDERSON J
This judgment was delivered by me on 15 April 2025 at 11.00 am pursuant to r 11.5 of the High Court Rules 2016.
………………………………
Registrar/Deputy Registrar
Solicitors:Minter Ellison Rudd Watts, Auckland Create IP, Auckland
MEDTECH LTD v VALENTIA TECHNOLOGIES (NZ) LTD [2025] NZHC 913 [15 April 2025]
[1] The plaintiff, Medtech, seeks leave to appeal two of my interlocutory judgments:1
(a)a judgment rescinding preservation orders dated 20 June 2024 (the Preservation Orders Judgment);2
(b)a costs order relating to the Preservation Orders Judgment dated 8 November 2024 (the Costs Judgment).3
[2] Medtech also seeks an extension of time in which to apply for leave to appeal the Preservation Orders Judgment. I grant an extension so that the leave issue can be dealt with directly.
[3] The applications are unusual. The gist of Medtech’s application is that in the Cost Judgment I concluded that Valentia was the successful party on the Preservation Orders Judgment when I should not have done. Medtech says this finding was in “error” because I had been misled by Valentia’s affidavit evidence to conclude in the Preservation Orders Judgment that without-notice preservation orders I made on 21 December 2024 (Preservation Orders) should not have been made.
[4]For the reasons outlined below, I dismiss the applications for leave to appeal.
Relevant procedural background
[5] The parties are competitors in the provision of patient/practice management software to medical practices (PMS). PMS is used for patient record-keeping and practice management at GP office practices and other health care providers. Medtech’s products are Medtech32 and a more recent product, Medtech Evolution. Valentia’s product is called indici. Medtech currently has 70 per cent of the market. Valentia has 17 per cent.
1 Pursuant to s 56(3) of the Senior Courts Act 2016, leave is required to pursue the interlocutory appeals.
2 Medtech Ltd v Valentia Technologies (NZ) Ltd [2024] NZHC 1618 (Preservation Orders Judgment).
3 Medtech Ltd v Valentia Technologies (NZ) Ltd [2024] NZHC 3315.
[6] On 19 December 2023, Medtech issued proceedings against Valentia alleging breaches of intellectual property rights, interference with contractual relations, breach of confidence, breach of a settlement of earlier litigation, and misleading conduct under the Fair Trading Act 1986. Medtech sought a range of interim orders without notice, including the Preservation Orders I made on 21 December 2024.4 The Preservation Orders were aimed at preserving a snapshot of the present version of Valentia’s software, associated intellectual property and operating environment so that Medtech could assess whether there had been a breach of its rights.
[7] In June 2024, I rescinded the Preservation Orders in the Preservation Orders Judgment. I also made orders for discovery…
Keep reading for free
Create a free CaseChat account to read Medtech Limited v Valentia Technologies (NZ) Limited and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2025] NZHC 913
- Decision Date
CaseChat Overview and Summary
The court found that Medtech's application was unusual, as it did not seek to challenge the outcome of the Preservation Orders Judgment but rather the reasons for it. The judge concluded that the application was more suited to a recall procedure than an appeal, as it sought to challenge the reasons for the judgment rather than the judgment itself. The judge further held that even if leave to appeal was appropriate, a strong factual platform was required to demonstrate that the court had been misled with material effect. The judge was not sufficiently persuaded that the court had been misled, as the inconsistencies in the affidavits provided by Valentia did not undermine the overall conclusions reached in the Preservation Orders Judgment.
The court dismissed the applications for leave to appeal and ordered costs in favour of Valentia on a 3B basis, meaning the costs would be paid by Medtech. The court found that the appeal would not serve the interests of justice and would be a waste of limited appellate court resources.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.